Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Casopitant and Paroxetine in Social Anxiety Disorder
NCT00273039Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2005
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of casopitant in Social Anxiety Disorder (SAD) (3 arms), sponsored by GSK. Primary endpoint: Liebowitz Social Anxiety Scale. Started Aug 2005; status: completed.
02
Drugs
casopitant
03
Conditions
Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on NCT00273039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00273039.